| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.1 | 0.005 |
| mRNA | GSK2636771 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.005 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.093 | 0.006 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.093 | 0.006 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.095 | 0.007 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.007 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.1 | 0.008 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | 0.098 | 0.008 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.097 | 0.008 |